Monitoring tyrosine kinase inhibitor therapeutic responses with a panel of metabolic biomarkers in chronic myeloid leukemia patients
This study showed that GC‐MS‐based metabolomics could provide a promising strategy for complementary diagnosis of CML and offer a new insight to monitor therapeutic responses of TKI in CML patients. Notably, myristic acid and glycerol may serve as a biomarker for characterizing CML patients and for the therapeutic responses of TKI.
Source: Cancer Science - Category: Cancer & Oncology Authors: Bingyu Yang, Chang Wang, Yiyu Xie, Liangjing Xu, Xiaojin Wu, Depei Wu Tags: ORIGINAL ARTICLE Source Type: research
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Leukemia | Science | Statistics | Study